U.S. Health Secretary Robert F. Kennedy Jr. announced plans to reform the National Vaccine Injury Compensation Program (VICP), pledging to address what he calls inefficiencies and corruption within the system. Kennedy, a long-time vaccine skeptic and former vaccine injury lawyer, criticized the program’s “Vaccine Court” for failing to quickly and fairly compensate individuals harmed by vaccines.
In a post on X, Kennedy said he is working with Attorney General Pam Bondi to restore the program to its “original congressional intent,” arguing that its current structure unfairly positions the Department of Health and Human Services (HHS), which he leads, as the defendant rather than vaccine manufacturers.
This move continues Kennedy’s sweeping efforts to reshape U.S. vaccine and health policy. In June, he dismissed all 17 members of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, replacing them with seven appointees, including figures with histories of questioning vaccine safety. One of these members previously earned significant fees as an expert witness against Merck’s Gardasil vaccine, a case in which Kennedy played a key role.
Kennedy is also reportedly considering removing members of another influential health advisory panel, the U.S. Preventive Services Task Force. His tenure at HHS has intensified scrutiny due to his longstanding promotion of vaccine skepticism, including discredited claims linking vaccines to autism and false statements about fetal cells in the measles vaccine.
The announcement comes amid one of the worst U.S. measles outbreaks in decades, further fueling debate over vaccine safety, public health policy, and Kennedy’s leadership approach.


Trump Bans CNN, MS NOW and Politico From White House
EU Defence Build-Up Too Slow for 2030 Russia Readiness Goal
Taiwan Thanks US for Support Ahead of Trump-Xi Summit
FDA Names Permanent Drug and Biologics Center Chiefs
US Immigration Arrests Surge as Deportations Lag Behind
Trump Administration Removes Confederate Memorial Criticism From Arlington Website
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
3 clinical-grade skincare creams you really shouldn’t buy online
Who should own the knowledge that underpins AI technology?
FCC Approves Foreign Investment in $110B Paramount-Warner Bros. Deal
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
Australia Tightens Student Visa Rules, Targets Migration Cut by 2028
White House Bars CNN, MS NOW and Politico Reporters
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 



